BioPharma Ambition 2020, an event that happens on March 3rd and 4th in Dublin Castle, is set to draw delegates from Ireland and across the world to deabte the future for medicines innovation and investments
Limited tickets are still available for the event which will explore the themes defining biopharmaceutical innovation right across the medicines lifecycle.
This year, like in 2016 and 2018, BioPharma Ambition will position Ireland at the nexus of globally networked innovation.
Some 400 delegates are expected in Dublin for the event, with experts covering topics like next-generation therapies, factory 4.0, tax, data and connected health, and the policy environment for a thriving biopharmaceutical industry.
The agenda is a blend of workshops, keynotes and moderated panels.
BioPharma Ambition 2020, which is supported by the government, is jointly organised by the biopharmaceutical industry’s representative organisations, IPHA and BPCI, and by NIBRT, a centre of excellence for training and research in bioprocessing.
The biopharmaceutical industry supports 30,000 jobs in Ireland and these are regionally distributed. What the industry produces accounts for more than 60% of the country’s goods exports.
“Ireland has potential in emerging areas like next-generation therapies, Industry 4.0, immunotherapies and genomics,” said Matt Moran, Director at BPCI. “With the right collaboration between industry and government, we can catch this new wave of biopharmaceutical innovation while sustaining the significant progress we have made in capturing investments in small and large-molecule medicines manufacturing,” he added.
Oliver O’Connor, Chief Executive at IPHA, said this year delegates will get a pre-read with recommendations for joint industry-government action for the future of biopharmaceutical innovation, as well as an independent analysis of Ireland’s strengths, weaknesses, opportunities and threats.
“This emerged from the BioPharma Policy Forum, a first-of-its-kind event we ran in December, in partnership with the government,” said Mr O’Connor. “At BioPharma Ambition 2020, we will try to answer many key questions. Have we thought enough about the availability of skills and talent? About tax policies to draw major manufacturing and research investments and, with them, people? About how we can protect the intellectual property rights that catalyse the development of new treatments? About how Ireland can improve the speed at which we adopt new medicines in the health services? We look forward to the engagement on these questions and more,” he added.
The partners behind BioPharma Ambition sincerely thank the sponsors for helping them to make the event happen: commercial partners PwC and McKesson; agency partners IDA Ireland, Enterprise Ireland, Science Foundation Ireland and InterTrade Ireland; and the many biopharmaceutical company patrons whose support and help is deeply appreciated.
See BioPharmaAmbition.com to buy tickets and get more information.